Uvea is found in the back of the sclera and the cornea and has three parts: the iris, the ciliary body and the choroid. Uveal melanoma, including the iris choroid and cilira body, is referred to as cancer of the areas of the skin. This is the state in which the tumors emerge from the melanocytes that are responsible for the color of the eye inside the uva.
It is the most common form of intraocular malignancy in adults, although it is an uncommon disorder. The treatment of uveal melanoma depends on the size of the tumor, which is the most significant factor. In the early stages, this kind of melanoma is completely asymptomatic. Some modifications can be observed in tumor enlargement over time, such as pupil distortion, reduced visibility due to blurred vision, and secondary retinal detachment.
This report contains market size and forecasts of Uveal Melanoma Treatment in Global, including the following market information:
Global Uveal Melanoma Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Uveal Melanoma Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Ciliary Melanoma Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Uveal Melanoma Treatment include Eli Lilly & Co., Spectrum Pharmaceuticals, Inc., Novartis AG, Bayer, Astra Zeneca plc, Merck, Amgen, Pfizer, Inc. and Roche. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Uveal Melanoma Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Uveal Melanoma Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Uveal Melanoma Treatment Market Segment Percentages, by Type, 2021 (%)
Ciliary Melanoma
Iris Melanoma
Choroid Melanoma
Global Uveal Melanoma Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Uveal Melanoma Treatment Market Segment Percentages, by Application, 2021 (%)
Hospitals
Ophthalmology Clinics
Others
Global Uveal Melanoma Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Uveal Melanoma Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Uveal Melanoma Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Uveal Melanoma Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Eli Lilly & Co.
Spectrum Pharmaceuticals, Inc.
Novartis AG
Bayer
Astra Zeneca plc
Merck
Amgen
Pfizer, Inc.
Roche